Emerging Pharmaceutical Markets Growth opportunities, changing healthcare dynamics and regulatory trends

The growth of emerging pharmaceutical markets remains impressively buoyant, having attained a 14.7% value increase over the 2005-06 period, a substantially greater rate than those witnessed within the developed markets of the EU and US. Although emergent markets proffer access to sizeable patient populations, significant barriers to entry continue to exist. For Western players, successful entry is contingent upon a comprehensive understanding of market dynamics, including differentiated growth prospects, sociopolitical structures and local market environments. Sustainable success can be derived from maintaining an acute awareness and timely exploitation of opportunities and threats that arise from healthcare financing systems, epidemiology and therapeutic forecasts, pricing and reimbursement policies, licensing sales trends, IP protection and leading player dynamics. Emerging Pharmaceutical Markets is a new report published by Business Insights, examining the external, regulatory and competitive environments of emergent markets in 24 countries across Asia, Central and Eastern Europe, and Latin America. The impact of licensing laws and reforms upon market penetration potential within these countries is assessed, and the trends that influence market opportunities are profiled. This report will also provide detailed analyses and forecasts to establish the future direction of emergent markets, and identify the key strategies necessary in securing successful market entry and sustainable growth. Use this report to evaluate the performance of pharma sales in 24 emergent countries, identify the key external and regulatory factors shaping these markets and assess the strategies of leading competitors.

Some key findings from this report

• Emerging pharma markets experienced a relatively strong CAGR of 16% between 2002-06, compared to the EU5 or US equivalents of 12.9% and 7.7% respectively. The catalysts for this growth include increased access to medicines, expanded healthcare formulatory listings and the availability of cheaper generics.

• The average percentage of GDP spent on healthcare in the combined emergent markets was 5.9%, or $18.1bn in 2004, as compared to 9.2%, or $919.3mn, for the EU5 during the same period.

• Latin America offers significant sales potential for ACE Inhibitors and analgesics, because of a high frequency of cardiovascular disorders across the region. Hypercholesterolemia, Latin America’s most common cardiovascular risk factor, had an estimated prevalence rate of 32% in 2004, and is forecast to rise to 34.6% by 2010.

• The five main therapeutic areas within emergent markets constituted 66.7% of total sales, or $49.6bn, in 2006, with alimentary,metabolic and anti-infective products leading the market. Systemic antibiotics and antacids continue to dominate growth.

• China has the largest healthcare spend of all emerging Asian economies, totalling $74.2bn in 2003. Korea and India are the next largest, with $41.1bn and $27.7bn respectively.

Key issues examined in this report

• The investment dilemma. Despite considerable challenges, emergent pharma markets will experience continued growth. Accession to the WTO has strengthened this trend, with stricter patent regimes now being developed and enforced.

• Cancer market potential. High levels of unmet need and weak capabilities in cancer treatment therapies have resulted in this therapeutic area having the strongest prospects for growth. Cyostatics and immunomodulatory agents hold the greatest demand potential.

• Generic vs branded products. Government endorsed production and a strong foundation for generics manufacturing have increased the use of generics in mainstream indications. As a result, it is unlikely that branded products can dominate emergent markets over the forecast period.

• Successful entry strategies. Although a number of entry strategies exist for MNC’s, these must be tailored according to a number of factors including organisational capability, portfolio development, governmental procurement priorities and barriers to entry within the chosen market.

Top five reasons to order your copy today

• Gain insights into the competitive dynamics of specific emergent pharma markets, using this report’s extensive qualitative and quantitative analysis of external growth drivers, leading therapeutic areas, pricing and reimbursement, and licensing trends.

• Discover the therapy ares with the greatest potential to stimulate franchise growth within individual emergent markets, and learn how to exploit these opportunities more effectively.

• Identify the key issues affecting both major pharma marketers and the development of branded and generic products, by accessing the latest competitive intelligence from across the emergent markets.

• Compare the healthcare systems and legislative developments of 24 emergent countries, and examine their impact upon pharma sales within their respective markets.

• Evaluate the strategies and product portfolios of leading pharma companies, and assess their responses to competitive change.

About the Author: Isabel Fraser-Moodie

Isabel Fraser-Moodie is an analyst within the healthcare practice of Business Insights. She previously worked in competitive intelligence, where she undertook several multinational pharmaceutical projects. Her areas of interest are drug discovery, R&D innovation and science policy specifically related to new medical innovations. Isabel graduated with a degree in Natural Sciences from Cambridge University, where she specialised in legislation targeting emergent genetic therapeutics and diagnostics.

Published: September 2007 - Global. Format PDF Pages 270
Table of Contents
Table of Contents PDF
Price: $2,875.00 / GBP1,437.50